Biocon Biologics has transitioned a portfolio of biosimilars including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, which has been commercialised by Viatris in the emerging markets
Biocon Research Centre in Biocon Park, Bengaluru, India. (Credit: Biocon)
Biocon Biologics, a subsidiary of Indian biopharmaceutical firm Biocon, has completed the integration of its acquired biosimilars business in more than 70 countries in Emerging Markets.
In November last year, BBL has completed its acquisition of the global biosimilars business of Viatris, formed through the merger of Mylan and Pfizer’s Upjohn division.
As the first wave, Viatris’ operations, including partners, people, systems, and processes across these countries, have been fully transitioned into Biocon Biologics.
The portfolio of biosimilars, including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, which has been managed by Viatris in these markets, is now a part of Biocon Biologics.
Biocon Biologics CEO and managing director Shreehas Tambe said: “The successful integration of Viatris’ biosimilars business to Biocon Biologics in over 70 countries is a significant milestone and marks the beginning of the transition process.
“Working closely with our partners, Biocon Biologics will now lead commercial operations in these markets and broaden access to patients with our differentiated portfolio of high quality biosimilars.
“This first wave in the transition process comes ahead of plan, thanks to the tireless efforts of our colleagues at both companies, our advisors and partners who worked relentlessly to make this happen.”
Biocon Biologics said that it will work closely with its existing and new partners to expand its footprint and strengthen business presence in these countries.
Leveraging its R&D capabilities, manufacturing, supply chain, and commercial and regulatory expertise, the company aims to expand its diverse portfolio of biosimilars in these markets.
It intends to continue the supply of biosimilar products offered by Viatris in various markets, covering key therapeutic areas of cancer, diabetes, and autoimmune disease.
Biocon Biologics said that most of the Viatris’ biosimilar products have been co-developed with the company and manufactured at its advanced facilities in India and Malaysia.
Biocon Biologics emerging markets chief commercial officer Susheel Umesh said: “The transitioning of these 70+ Emerging Markets to Biocon Biologics from Viatris marks the first phase of the business integration plan charted out for the acquired business.
This will allow Biocon Biologics to meaningfully expand the geographic reach of the existing biosimilars portfolio and future pipeline into growth markets where Viatris has existing sales infrastructure and local market expertise.
“Working closely with key stakeholders in these markets will allow us to ensure reliable supplies of our biosimilars for those who need them the most, while enabling us to capitalize on the rapidly expanding global biosimilars opportunity.”